UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008802
Receipt number R000010284
Scientific Title Safety trial of eriburin treatment to patient who has peripheral neuropathy
Date of disclosure of the study information 2012/09/01
Last modified on 2019/02/28 13:43:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety trial of eriburin treatment to patient who has peripheral neuropathy

Acronym

H(Hiroshima)-STEP

Scientific Title

Safety trial of eriburin treatment to patient who has peripheral neuropathy

Scientific Title:Acronym

H(Hiroshima)-STEP

Region

Japan


Condition

Condition

Breast Cancer

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate safety of Eribulin in breast cancer patients with peropheral neuropathy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Incidence rates of peripheral neuropathy G3(CTCAE)

Key secondary outcomes

Response Rate
Overall Survival
FACT-NTX EQ-5D
Safety
PNQ


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1) Histologically or cytologically confirmed breast cancer.
2) Unresectable metastatic breast cancer.
3)Previously treated with chemotherapeutic regimens including an anthracycline and a taxane first-line chemotherapy
4)Having evaluable disease according to RECIST
5)Prior chemotherapy 0-2 regimens for unresectable metastatic status
6)Having an adequate interval from prior therapy
1.chemotherapy:21days
2.endocrine therapy:7days
3.radiation therapy:14days
4.major surgery:28days
5.minor surgery:14days
6)PS (ECOG) 0-2
7)Eligible patient for eribulin therapy
8)Peripheral neuropathy G1 or G0(experienced peripheral neuropathy caused from previous chemotherapy)
9)Adequate organ functions
1.neutrophil=>1000mm3
2.platelet count=>75000mm3
3.AST,ALT=<2.5 times ULN(<5.0 with liver metastasis)
4.total bilirubin=<1.5 times ULN
serum creatinine=<1.5mg/dL
10)Female over 20 years old
11)Obtained written informed consent

Key exclusion criteria

1)Forbidden case to use eribulin
2)Serious bone marrow suppression
3)Allergy to component of eribulin
4)Pregnant or like be pregnant
5)Serious liver or renal disorder
6)Inadequate interval from prior therapy
7)Symptomatic brain metastasis
8)Patient with CNS disease, DM, RA, or bone metastasis (possible involvement peripheral neropathy)
9)Peripheral neuropathy caused from surgery
10)With doctors decision for exclusion

Target sample size

48


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Morihito Okada

Organization

Hiroshima Unversity Hospital

Division name

Department of surgical oncology

Zip code


Address

1-2-3 Kasumi, Minami-ku, Hiroshima

TEL

082-257-5869

Email

morihito1217@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Hideo Shigematsu

Organization

Hiroshima Unversity Hospital

Division name

Department of surgical oncology

Zip code


Address

1-2-3 Kasumi, Minami-ku, Hiroshima

TEL

082-257-5869

Homepage URL


Email

shsasada@hiroshima-u.ac.jp


Sponsor or person

Institute

Dept of surgical oncology, Hiroshima university hospital

Institute

Department

Personal name



Funding Source

Organization

Dept of surgical oncology, Hiroshima university hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 09 Month 01 Day

Date of IRB


Anticipated trial start date

2012 Year 09 Month 01 Day

Last follow-up date

2019 Year 01 Month 31 Day

Date of closure to data entry

2019 Year 01 Month 31 Day

Date trial data considered complete

2019 Year 02 Month 08 Day

Date analysis concluded

2019 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2012 Year 08 Month 30 Day

Last modified on

2019 Year 02 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010284


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name